4.7 Article

Biodegradable organosilica-based targeted and redox-responsive delivery system of resveratrol for efficiently alleviating ulcerative colitis

Journal

JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY
Volume 123, Issue -, Pages 382-395

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jiec.2023.03.055

Keywords

Organosilica; Resveratrol; Chondroitin sulfate; Redox-responsive release; Ulcerative colitis

Ask authors/readers for more resources

Ulcerative colitis (UC) is a disease with a low redox potential in the colon. Resveratrol (Res), a natural ingredient with anti-inflammatory properties, has limited bioavailability and poor solubility in water, which hinders its clinical use. In this study, Res-encapsulated tetrasulfide-containing organosilica nanoparticles (DSMSNs) were developed as an oral delivery carrier, and the targeted delivery of Res to colon epithelial cells and macrophages was achieved through the use of chondroitin sulfate (CS) and a glutathione (GSH) response-mediated disassembly.
Ulcerative colitis (UC) is characterized by a low redox potential in the colon. Targeting redox-responsive strategies are highly desirable due to the capacity of improving the treatment efficiency of drugs against UC. Resveratrol (Res), a natural ingredient, possesses prominent anti-inflammatory activity. However, the limited bioavailability and poor water-solubility severely hinder its clinical translation. Herein, we fabricate an oral delivery carrier of Res-encapsulated tetrasulfide-containing organosilica nanoparticles (DSMSNs), functionalized by targeting component chondroitin sulfate (CS). Benefiting from smart switch and targeted guider, CS shell enables high internalization and promotes selective accumulation in colon epithelial cells and macrophages through CD44-mediated pathway; meanwhile, glutathione (GSH) response-mediated rapid disassembly exhibits targeted Res release and efficient biodegradation, consequently achieving enhanced intracellular delivery of Res, improved Res-enabled treatment and recovered gut microbial diversity in the colitis model to mitigate colonic inflammation. These findings thus bring fresh insights into the potential of MONs in UC treatment as an oral delivery platform. (c) 2023 The Korean Society of Industrial and Engineering Chemistry. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available